EULAR 2021 Janssen-Sponsored symposium: “The launching pad: exploring the potential of the IL-23 pathway in psoriatic arthritis.” - European Medical Journal

Continue

EULAR 2021 Janssen-Sponsored symposium: “The launching pad: exploring the potential of the IL-23 pathway in psoriatic arthritis.”

Rheumatology
General Healthcare
Bonus Episode

EULAR 2021 Janssen-Sponsored symposium: “The launching pad: exploring the potential of the IL-23 pathway in psoriatic arthritis.”

Discussing presentations from experts Georg Schett, Freidrich-Alexander University, Erlangen-Nürnberg, Germany; Stefan Siebert, University of Glasgow, UK; and Christopher Griffiths, University of Manchester, UK, the first podcast reviews evidence exploring the potential of the IL-23 pathway in PsA. The discussions highlight both the role highlight both the role of the IL-23 pathway in the pathogenesis of PsA and the potential IL-23 inhibitors hold for improving PsA outcomes.

Spotify | Apple | Download MP3 (mp 11:35 mins)

 

This podcast is supported by Janssen Pharmaceutical Companies of Johnson & Johnson. The views expressed in this podcast are those of the individual speaker and do not necessarily reflect the views of Janssen Pharmaceutical Companies of Johnson & Johnson.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given